Back to top

Nuvation Bio Moves Safusidenib Into Phase 3, Raising Stakes in Targeted Brain Cancer

Nuvation Bio Inc ($NUVB) announced an update on their ongoing clinical study. Nuvation Bio Inc. has launched a pivotal Phase 3 study called “A Phas...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nuvation Bio Inc. (NUVB)